PD-1 /PD-L1 checkpoint in hematological malignancies

Annibali, Ombretta; Crescenzi, Anna; Tomarchio, Valeria; Pagano, Anastasia; Bianchi, Antonella; Grifoni, Alba; Avvisati, Giuseppe

doi:10.1016/j.leukres.2018.01.014

Cited by 40 publications

(30 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PD-1, a receptor on T lymphocytes, limits adaptive immune response and prevents auto-inflammatory and autoimmune reaction. [ 13 ] In cancer patients, PD-1 expression is higher on tumor-infiltrating T lymphocytes, PD-1 transmits inhibitory signals into T cells after ligation with PD-1 ligands, PD-L1 [ 14 ] and PD-L2 [ 15 ] expressed on neoplastic cells. The PD-L1 is variably expressed on the surface of cancer cells and antigen-presenting cells within tumors tissues, providing a potent inhibitory signal within tumor microenvironment.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma

et al. 2020

View full text Add to dashboard Cite

This study aimed to investigate the prognostic value of PD-L1 in Chinese patients with non-small cell lung carcinoma (NSCLC). In this retrospective study, 97 patients with NSCLC were consecutively recruited. The expression profiling of PD-1, PD-L1, p53 and Ki-67 was detected by immunohistochemistry. Median survival time was estimated by Kaplan–Meier survival curve with log-rank test. Risk factors were evaluated by Cox Proportional Hazards regression models. The median tumor size was larger (3.5 cm) among patients with positive PD-L1 expression, compared to those with negative expression (2.0 cm; P < .01). Compared to those with negative PD-L1 expression, patients with positive PD-L1 expression had significantly higher rates of nerve invasion (26.3% vs 5.0%; P < .01), blood vessel invasion (47.4% vs 20.0%; P < .01) and lymph node metastasis (64.9% vs 27.5%; P < .01), more advanced tumor stage ( P < .01) and Ki-67 index ( P < .01). PD-L1 expression status was not significantly associated with disease-free (DFS) or overall survival (OS). However, for patients with advanced disease, PD-L1 positive expression was related to worse outcome (HR: 4.13; 95% CI: 1.06–16.12). Positive PD-L1 expression is associated with more aggressive pathological features and poorer prognosis in advanced stage NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In this special issue, we also elucidate antibody-based therapies in AML, such as T cell activating antibodies including immune-checkpoint inhibitors and diverse monoclonal antibodies [11,12,24]. Immune-checkpoint inhibitors have changed clinical treatment algorithms of malignant diseases such as malignant melanoma, lung cancer, as well as lymphoma.…”

mentioning

confidence: 99%

The Important Role of Immunotherapies in Acute Myeloid Leukemia

Greiner

2019

JCM

View full text Add to dashboard Cite

show abstract

“…PD-1 is a checkpoint receptor on T lymphocytes, plays an important role in limiting adaptive immune responses and prevents auto-inflammatory and autoimmune reactivity [13]. In cancer patients, PD-1 expression is higher on T tumor-infiltrating lymphocytes, PD-1 transmits inhibitory signals into T cells after ligation with PD-1 ligands, PD-L1 [14] and PD-L2 [15] on neoplastic cells.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma patients: a cohort study at a single institute

Zhao¹,

Shi²,

Zhou³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background This study aimed to investigate the prognostic effect of PD-L1 on Chinese non-small cell lung carcinoma patients.Methods A retrospective cohort study was conducted and consecutively recruited 97 patients with non-small cell lung carcinoma. The expression status of PD-1, PD-L1, p53 and Ki-67 was detected by immunohistochemistry. Kaplan-Meier survival curve with log-rank test was used to estimate survival. Cox-Hazard Proportion regression model was used to estimate the hazard ratio and 95% confidence intervalResults The median tumor size was 3.5 cm and 2.0 cm among patients with positive and negative PD-L1 expression, respectively (p<0.001). The proportion of patients with positive and negative PD-L1 expression having nerve invasion was 26.3% and 5.0% (p<0.01). 47.4% patients with positive PD-L1 expression had blood vessel invasion compared with 20.0% patients with negative PD-L1 expression (p<0.01). 64.9% patients with positive PD-L1 expression had lymph node metastasis compared with 27.5% patients with negative PD-L1 expression (p<0.001). Patients with positive PD-L1 expression were more likely to be in advanced stage (p<0.001) and had higher Ki-67 index (p<0.01). PD-L1 expression status did not show any significant association with DFS or OS. However among advanced patients, HR of PD-L1 expression was 4.13 (95%CI 1.06, 16.12).Conclusions Positive PD-L1 expression is associated with poorer prognosis in advanced stage patients. Compare to patients with negative expression, patients with positive PD-L1 expression had more aggressive pathological features. Further prospective studies are needed to confirm the results.

show abstract

PD-1 /PD-L1 checkpoint in hematological malignancies

Cited by 40 publications

References 105 publications

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma

The Important Role of Immunotherapies in Acute Myeloid Leukemia

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma patients: a cohort study at a single institute

Contact Info

Product

Resources

About